Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.56
BIO's Cash-to-Debt is ranked lower than
57% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.32 vs. BIO: 1.56 )
Ranked among companies with meaningful Cash-to-Debt only.
BIO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.56 Max: N/A
Current: 1.56
Equity-to-Asset 0.69
BIO's Equity-to-Asset is ranked higher than
64% of the 216 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. BIO: 0.69 )
Ranked among companies with meaningful Equity-to-Asset only.
BIO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.51 Max: 0.69
Current: 0.69
0.33
0.69
Interest Coverage 2.48
BIO's Interest Coverage is ranked lower than
88% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.14 vs. BIO: 2.48 )
Ranked among companies with meaningful Interest Coverage only.
BIO' s Interest Coverage Range Over the Past 10 Years
Min: 2.42  Med: 5.04 Max: 7.69
Current: 2.48
2.42
7.69
Piotroski F-Score: 4
Altman Z-Score: 4.79
Beneish M-Score: -2.62
WACC vs ROIC
7.49%
1.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 2.53
BIO's Operating Margin % is ranked higher than
50% of the 221 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. BIO: 2.53 )
Ranked among companies with meaningful Operating Margin % only.
BIO' s Operating Margin % Range Over the Past 10 Years
Min: 2.53  Med: 9.81 Max: 14.74
Current: 2.53
2.53
14.74
Net Margin % 1.35
BIO's Net Margin % is ranked higher than
54% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. BIO: 1.35 )
Ranked among companies with meaningful Net Margin % only.
BIO' s Net Margin % Range Over the Past 10 Years
Min: 1.35  Med: 5.98 Max: 9.63
Current: 1.35
1.35
9.63
ROE % 1.07
BIO's ROE % is ranked higher than
52% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. BIO: 1.07 )
Ranked among companies with meaningful ROE % only.
BIO' s ROE % Range Over the Past 10 Years
Min: 1.07  Med: 8.85 Max: 13.27
Current: 1.07
1.07
13.27
ROA % 0.73
BIO's ROA % is ranked higher than
56% of the 237 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.39 vs. BIO: 0.73 )
Ranked among companies with meaningful ROA % only.
BIO' s ROA % Range Over the Past 10 Years
Min: 0.73  Med: 4.77 Max: 6.63
Current: 0.73
0.73
6.63
ROC (Joel Greenblatt) % 5.86
BIO's ROC (Joel Greenblatt) % is ranked higher than
53% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.64 vs. BIO: 5.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 5.86  Med: 25.09 Max: 36.51
Current: 5.86
5.86
36.51
3-Year Revenue Growth Rate -1.80
BIO's 3-Year Revenue Growth Rate is ranked lower than
68% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. BIO: -1.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BIO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.8  Med: 8.3 Max: 21
Current: -1.8
-1.8
21
3-Year EBITDA Growth Rate -14.40
BIO's 3-Year EBITDA Growth Rate is ranked lower than
74% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.60 vs. BIO: -14.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BIO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -14.4  Med: 8.4 Max: 40.2
Current: -14.4
-14.4
40.2
3-Year EPS without NRI Growth Rate -29.30
BIO's 3-Year EPS without NRI Growth Rate is ranked lower than
83% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. BIO: -29.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BIO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -36.8  Med: 10.2 Max: 112
Current: -29.3
-36.8
112
GuruFocus has detected 5 Warning Signs with Bio-Rad Laboratories Inc $BIO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIO's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:NAS:INCR, NAS:DXCM, NYSE:PKI, NYSE:CRL, NAS:PRAH, NAS:BRKR, NAS:PRXL, NYSE:ALR, NAS:VWR, NAS:EXAS » details
Traded in other countries:BUWA.Germany,
Headquarter Location:USA
Bio-Rad Laboratories Inc manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials.

Bio-Rad Laboratories Inc was founded in 1952 and incorporated in 1957. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates in two industry segments designated as Life Science and Clinical Diagnostics. Life science is the study of the characteristics, behavior, and structure of living organisms and their component systems. Life Science segment is at the forefront of discovery, creating tools to answer complex biological questions. The Company is engaged in developing, manufacturing and marketing a range of more than 5,000 reagents, apparatus and laboratory instruments that serve a wide customer base. Many of its products are used in established research techniques, biopharmaceutical production processes and food testing regimes. These techniques are typically used to separate, purify and identify biological materials such as proteins, nucleic acids and bacteria within a laboratory or production setting. Its main life science customers include universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers and food testing laboratories. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the diagnostics market. Its products currently address specific niches within the in vitro diagnostics (IVD) test market. It supplies more than 3,000 different products that cover more than 300 clinical diagnostic tests to the IVD test market. IVD tests are conducted outside the human body and are used to identify and measure substances in a patient's tissue, blood or urine. Its products consist of reagents, instruments and software, typically provided to its customers as an integrated package to allow them to generate reproducible test results. Its main clinical diagnostic customers include hospital laboratories, reference laboratories, transfusion laboratories and physician office laboratories. The Company owns numerous U.S. and international patents and patent licenses. Each of the Company's segments maintains a sales force to sell its products on a direct basis. Major competitors in the clinical diagnostic segment include Roche, Abbott Laboratories (Diagnostic Division), Siemens Medical Diagnostics Solutions (formerly Dade-Behring, Diagnostics Products Corporation, and Bayer Diagnostics), Beckman Coulter, Becton-Dickinson, bioMérieux, Johnson & Johnson (Ortho Clinical Diagnostics), Thermo Fisher, Tosoh, Immucor, Cepheid, and DiaSorin. The Company's operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissio

Top Ranked Articles about Bio-Rad Laboratories Inc

Bio-Rad to Report Third-Quarter 2016 Financial Results Tuesday, November 1, 2016

HERCULES, CA--(Marketwired - Oct 10, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, will report financial results for the third quarter 2016 on Tuesday, November 1, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To listen, call 855-779-9068 within the U.S. or 631-485-4862 outside the U.S., Conference ID: 93613814. You may also listen to the conference call live via a webcast that is available on the "Investor Relations" section of our website under "Quarterly Results" at www.bio-rad.com. The webcast will be available for up to a year.  About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 8,000 people worldwide and had revenues exceeding $2 billion in 2015. For more information, please visit www.bio-rad.com.


Investor and Financial Contacts:

Christine Tsingos

Executive Vice President and Chief Financial Officer

Ron Hutton

Vice President and Treasurer

Bio-Rad Laboratories, Inc.

510-724-7000





Read more...
Mariko Gordon Invested in 5 Companies in 2nd Quarter Guru's top new purchases were shares of ABM Industries, Comfort Systems, Invacare
Three of Mariko Gordon (Trades, Portfolio)’s five largest second-quarter transactions for Daruma Capital Management were investments in companies that are new to the portfolio – ABM Industries Inc. (NYSE:ABM), Comfort Systems USA Inc. (NYSE:FIX) and Invacare Corp. (NYSE:IVC). Read more...

Ratios

vs
industry
vs
history
PE Ratio 237.75
BIO's PE Ratio is ranked lower than
94% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.35 vs. BIO: 237.75 )
Ranked among companies with meaningful PE Ratio only.
BIO' s PE Ratio Range Over the Past 10 Years
Min: 13.66  Med: 23.13 Max: 242.93
Current: 237.75
13.66
242.93
Forward PE Ratio 63.29
BIO's Forward PE Ratio is ranked lower than
95% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.63 vs. BIO: 63.29 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 237.75
BIO's PE Ratio without NRI is ranked lower than
94% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.61 vs. BIO: 237.75 )
Ranked among companies with meaningful PE Ratio without NRI only.
BIO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.66  Med: 23.13 Max: 242.93
Current: 237.75
13.66
242.93
PB Ratio 2.43
BIO's PB Ratio is ranked higher than
72% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. BIO: 2.43 )
Ranked among companies with meaningful PB Ratio only.
BIO' s PB Ratio Range Over the Past 10 Years
Min: 1.45  Med: 1.81 Max: 3.02
Current: 2.43
1.45
3.02
PS Ratio 3.14
BIO's PS Ratio is ranked higher than
57% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.61 vs. BIO: 3.14 )
Ranked among companies with meaningful PS Ratio only.
BIO' s PS Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.59 Max: 3.24
Current: 3.14
0.87
3.24
Price-to-Free-Cash-Flow 523.34
BIO's Price-to-Free-Cash-Flow is ranked lower than
99% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.66 vs. BIO: 523.34 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BIO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.64  Med: 25.61 Max: 534.78
Current: 523.34
9.64
534.78
Price-to-Operating-Cash-Flow 39.49
BIO's Price-to-Operating-Cash-Flow is ranked lower than
77% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.27 vs. BIO: 39.49 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BIO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.5  Med: 13.1 Max: 40.37
Current: 39.49
7.5
40.37
EV-to-EBIT 101.27
BIO's EV-to-EBIT is ranked lower than
94% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.02 vs. BIO: 101.27 )
Ranked among companies with meaningful EV-to-EBIT only.
BIO' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.4  Med: 13.6 Max: 104.7
Current: 101.27
8.4
104.7
EV-to-EBITDA 31.01
BIO's EV-to-EBITDA is ranked lower than
75% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.53 vs. BIO: 31.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6  Med: 9.35 Max: 32.1
Current: 31.01
6
32.1
Shiller PE Ratio 50.59
BIO's Shiller PE Ratio is ranked lower than
58% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 46.11 vs. BIO: 50.59 )
Ranked among companies with meaningful Shiller PE Ratio only.
BIO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.49  Med: 28.78 Max: 51.66
Current: 50.59
19.49
51.66
Current Ratio 4.25
BIO's Current Ratio is ranked higher than
69% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.72 vs. BIO: 4.25 )
Ranked among companies with meaningful Current Ratio only.
BIO' s Current Ratio Range Over the Past 10 Years
Min: 1.49  Med: 2.58 Max: 4.52
Current: 4.25
1.49
4.52
Quick Ratio 2.88
BIO's Quick Ratio is ranked higher than
60% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. BIO: 2.88 )
Ranked among companies with meaningful Quick Ratio only.
BIO' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 1.66 Max: 3.45
Current: 2.88
0.82
3.45
Days Inventory 208.05
BIO's Days Inventory is ranked lower than
89% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 82.10 vs. BIO: 208.05 )
Ranked among companies with meaningful Days Inventory only.
BIO' s Days Inventory Range Over the Past 10 Years
Min: 156.44  Med: 173.53 Max: 208.05
Current: 208.05
156.44
208.05
Days Sales Outstanding 65.00
BIO's Days Sales Outstanding is ranked lower than
54% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.14 vs. BIO: 65.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.37  Med: 70.54 Max: 89.45
Current: 65
63.37
89.45
Days Payable 50.98
BIO's Days Payable is ranked lower than
60% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.94 vs. BIO: 50.98 )
Ranked among companies with meaningful Days Payable only.
BIO' s Days Payable Range Over the Past 10 Years
Min: 43.27  Med: 52.25 Max: 56.81
Current: 50.98
43.27
56.81

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.90
BIO's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. BIO: -0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.3  Med: -1 Max: -0.2
Current: -0.9
-1.3
-0.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 13.54
BIO's Price-to-Net-Current-Asset-Value is ranked lower than
60% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.67 vs. BIO: 13.54 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BIO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.86  Med: 7.05 Max: 95.94
Current: 13.54
2.86
95.94
Price-to-Tangible-Book 3.31
BIO's Price-to-Tangible-Book is ranked higher than
69% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.04 vs. BIO: 3.31 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BIO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.73  Med: 2.49 Max: 6.43
Current: 3.31
0.73
6.43
Price-to-Intrinsic-Value-Projected-FCF 2.22
BIO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
53% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. BIO: 2.22 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BIO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.78  Med: 1.41 Max: 20.39
Current: 2.22
0.78
20.39
Price-to-Median-PS-Value 1.99
BIO's Price-to-Median-PS-Value is ranked lower than
90% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. BIO: 1.99 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 0.69 Max: 2.02
Current: 1.99
0.14
2.02
Price-to-Graham-Number 5.90
BIO's Price-to-Graham-Number is ranked lower than
79% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. BIO: 5.90 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BIO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.66  Med: 1.47 Max: 6
Current: 5.9
0.66
6
Earnings Yield (Greenblatt) % 0.98
BIO's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.52 vs. BIO: 0.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.97  Med: 7.3 Max: 11.9
Current: 0.98
0.97
11.9
Forward Rate of Return (Yacktman) % -10.70
BIO's Forward Rate of Return (Yacktman) % is ranked lower than
91% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.56 vs. BIO: -10.70 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BIO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -10.7  Med: 10.15 Max: 22.4
Current: -10.7
-10.7
22.4

More Statistics

Revenue (TTM) (Mil) $2,097.03
EPS (TTM) $ 0.94
Beta0.93
Short Percentage of Float3.26%
52-Week Range $135.94 - 230.40
Shares Outstanding (Mil)29.61

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,173 2,269 2,367
EPS ($) 3.52 4.44 5.46
EPS without NRI ($) 3.52 4.44 5.46
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for BIO

Headlines

Articles On GuruFocus.com
Bio-Rad to Report Third-Quarter 2016 Financial Results Tuesday, November 1, 2016 Oct 10 2016 
Mariko Gordon Invested in 5 Companies in 2nd Quarter Aug 21 2016 
Bio-Rad Unveils Amplichek II Quality Control, the First in a Series of Controls for the Molecular Di May 23 2016 
Bio-Rad to Report First-Quarter 2016 Financial Results Thursday, May 5, 2016 Apr 13 2016 
Bio-Rad Announces CE IVD Marking of Its QX200 Droplet Digital PCR System for Use as an In Vitro Diag Feb 25 2016 
CORRECTION - Bio-Rad to Report Fourth-Quarter and Full-Year 2015 Financial Results Thursday, Februar Feb 16 2016 
Bio-Rad Expands Its Cell Biology Portfolio With High Performance Flow Cytometer Feb 08 2016 
Bio-Rad to Report Fourth-Quarter and Full-Year 2015 Financial Results Thursday, February 25, 2016 Feb 02 2016 
Bio-Rad Joins Food Safety Consortium With IBM and Mars, Incorporated Jan 12 2016 
Bio-Rad Named One of the 2015 Top 100 Bay Area Innovators by Thomson Reuters Jan 05 2016 

More From Other Websites
Bio-Rad (BIO) Scores a Strong Buy Right Now: Here's How Jun 22 2017
ETFs with exposure to Bio-Rad Laboratories, Inc. : June 19, 2017 Jun 19 2017
Bio-Rad Laboratories, Inc. :BIO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Jun 16 2017
Health Care Battle Rages On: 2 MedTech Stocks to Buy Jun 16 2017
Bio-Rad Announces FDA Clearance of its BioPlex 2200 Syphilis Total & RPR Assay, a Novel Syphilis... Jun 12 2017
Imprimis Pharmaceuticals (IMMY) Looks Good: Stock Up 13% Jun 02 2017
Bio-Rad Introduces Enhanced Options with its IH-Com Data Management Software for Managing Patient... May 24 2017
What Bio-Rad Laboratories Expects from Life Science May 23 2017
Inside Bio-Rad Laboratories’ Profit Margin Expectations in 2017 May 22 2017
Inside Bio-Rad Laboratories’ Robust Revenue Growth Projection for 2017 May 22 2017
Bio-Rad Laboratories on the Street: Analysts’ Recommendations in May May 22 2017
TransEnterix (TRXC) Reports Wider-than-Expected Loss in Q1 May 15 2017
Medtronic (MDT) Wins FDA Approval for CRT-P SureScan Suite May 12 2017
STERIS (STE) Grapples with Headwinds: Should You Dump? May 12 2017
Genomic Health (GHDX) Misses Q1 Earnings & Sales Estimates May 11 2017
Dull Q1 Earnings & Tough Industry Spell Trouble for BioScrip May 11 2017
Becton (BDX) Announces $4.5B Follow-On Share Offerings May 11 2017
Edited Transcript of BIO earnings conference call or presentation 4-May-17 9:00pm GMT May 09 2017
New Strong Buy Stocks for May 9th May 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}